Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update

• Published in: Journal of pharmacy practice Vol. 33; no. 6; pp. 882 - 894
• Main Authors: Wiggins, Barbara S., Dixon, Dave, Bellone, Jessica, Gasbarro, Nicole, Marrs, Joel C., Tran, Rebecca
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-12-2020
• Subjects: Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Risk Factors; United States; United States; dyslipidemia; PCSK9; statins
• ISSN: 0897-1900; 1531-1937
• DOI: 10.1177/0897190019868413

Although the mortality from cardiovascular disease has declined, it remains the leading cause of morbidity and mortality in the United States. Dyslipidemia is a modifiable risk factor that plays a significant role in the development of atherosclerotic cardiovascular disease. Treating dyslipidemia by lowering cholesterol, predominately low-density lipoprotein cholesterol, has been shown to reduce cardiovascular events. The first article that provided dyslipidemia bibliographies was published in 2006. Since this time, new therapies have become available and older therapies that were once thought to provide benefit have since been shown to lack positive outcomes and have therefore fallen out of favor for routine use. As the body of evidence continues to expand, clinicians are faced with reevaluating their treatment strategies to ensure optimal outcomes and appropriate use of lipid-lowering therapies. Therefore, this compilation was created to serve as a resource for clinicians. This publication provides an update of key articles in dyslipidemia management including various guidelines and practice-changing randomized controlled trials.